- Home
- BKH vs GH Comparison
BKH vs GH Comparison
Compare BKH & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKH
- GH
- Stock Information
- Founded
- BKH 1941
- GH 2011
- Country
- BKH United States
- GH United States
- Employees
- BKH N/A
- GH N/A
- Industry
- BKH Electric Utilities: Central
- GH Medical Specialities
- Sector
- BKH Utilities
- GH Health Care
- Exchange
- BKH Nasdaq
- GH Nasdaq
- Market Cap
- BKH 4.4B
- GH 4.3B
- IPO Year
- BKH N/A
- GH 2018
- Fundamental
- Price
- BKH $59.69
- GH $34.64
- Analyst Decision
- BKH Hold
- GH Strong Buy
- Analyst Count
- BKH 4
- GH 15
- Target Price
- BKH $61.25
- GH $39.93
- AVG Volume (30 Days)
- BKH 421.7K
- GH 1.5M
- Earning Date
- BKH 02-05-2025
- GH 11-06-2024
- Dividend Yield
- BKH 4.31%
- GH N/A
- EPS Growth
- BKH N/A
- GH N/A
- EPS
- BKH 3.68
- GH N/A
- Revenue
- BKH $2,122,300,000.00
- GH $692,256,000.00
- Revenue This Year
- BKH N/A
- GH $32.23
- Revenue Next Year
- BKH $3.36
- GH $16.90
- P/E Ratio
- BKH $16.33
- GH N/A
- Revenue Growth
- BKH N/A
- GH 29.20
- 52 Week Low
- BKH $49.34
- GH $15.81
- 52 Week High
- BKH $65.59
- GH $38.53
- Technical
- Relative Strength Index (RSI)
- BKH 35.42
- GH 58.28
- Support Level
- BKH $59.75
- GH $34.20
- Resistance Level
- BKH $61.37
- GH $36.24
- Average True Range (ATR)
- BKH 0.83
- GH 1.40
- MACD
- BKH -0.39
- GH -0.54
- Stochastic Oscillator
- BKH 5.10
- GH 12.70
About BKH Black Hills Corporation
Black Hills Corp is a U.S.-based energy company that operates through its Electric Utilities, Gas Utilities, Corporate and Other segments. These segments operate in states in the Midwest and mountain regions in the U.S. The company's customers include residential, commercial, industrial, and municipal consumers. These customers are residential. Black Hills derives the majority of its revenue from its utility business group, specifically from electric utilities.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.